Last reviewed · How we verify
Blood components transfusion
Blood components transfusion replaces deficient or lost blood cells and plasma factors to restore oxygen-carrying capacity, hemostasis, and immune function.
Blood components transfusion replaces deficient or lost blood cells and plasma factors to restore oxygen-carrying capacity, hemostasis, and immune function. Used for Acute hemorrhage requiring volume and oxygen-carrying capacity restoration, Severe anemia, Thrombocytopenia with bleeding risk.
At a glance
| Generic name | Blood components transfusion |
|---|---|
| Sponsor | Oregon Health and Science University |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Transfusion of blood components (red blood cells, platelets, plasma, cryoprecipitate) directly replenishes circulating blood elements lost through hemorrhage, hemolysis, or bone marrow failure. This restores oxygen delivery to tissues, corrects coagulopathy, and supports immune function. The mechanism is physiologic replacement rather than pharmacologic.
Approved indications
- Acute hemorrhage requiring volume and oxygen-carrying capacity restoration
- Severe anemia
- Thrombocytopenia with bleeding risk
- Coagulopathy or clotting factor deficiency
- Bone marrow failure or aplasia
Common side effects
- Transfusion reaction (acute hemolytic)
- Transfusion-related acute lung injury (TRALI)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Infection (viral, bacterial, parasitic)
- Iron overload (with chronic transfusion)
Key clinical trials
- Study of Transfusion-Transmitted Infections
- INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (PHASE3)
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures (NA)
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (PHASE4)
- Bortezomib in Rejection of Kidney Transplants (PHASE2)
- Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |